Polyrizon (PLRZ) Competitors $0.0035 0.00 (-16.67%) As of 12:16 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock PLRZ vs. UPC, NCNA, HSTO, SMFL, ADTX, SCPS, EVLO, GNCAQ, GNCA, and ARDSShould you be buying Polyrizon stock or one of its competitors? The main competitors of Polyrizon include Universe Pharmaceuticals (UPC), NuCana (NCNA), Histogen (HSTO), Smart for Life (SMFL), Aditxt (ADTX), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), and Aridis Pharmaceuticals (ARDS). These companies are all part of the "pharmaceutical products" industry. Polyrizon vs. Universe Pharmaceuticals NuCana Histogen Smart for Life Aditxt Scopus BioPharma Evelo Biosciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Polyrizon (NASDAQ:PLRZ) and Universe Pharmaceuticals (NYSE:UPC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability. Does the MarketBeat Community favor PLRZ or UPC? Polyrizon and Universe Pharmaceuticals both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformPolyrizonN/AN/AUniverse PharmaceuticalsN/AN/A Do institutionals & insiders hold more shares of PLRZ or UPC? 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media refer more to PLRZ or UPC? In the previous week, Polyrizon had 2 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 2 mentions for Polyrizon and 0 mentions for Universe Pharmaceuticals. Polyrizon's average media sentiment score of 0.84 beat Universe Pharmaceuticals' score of 0.00 indicating that Polyrizon is being referred to more favorably in the media. Company Overall Sentiment Polyrizon Positive Universe Pharmaceuticals Neutral Which has preferable valuation and earnings, PLRZ or UPC? Polyrizon has higher earnings, but lower revenue than Universe Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPolyrizonN/AN/AN/AN/AN/AUniverse Pharmaceuticals$23.02M0.01-$6.16MN/AN/A Is PLRZ or UPC more profitable? Company Net Margins Return on Equity Return on Assets PolyrizonN/A N/A N/A Universe Pharmaceuticals N/A N/A N/A SummaryUniverse Pharmaceuticals beats Polyrizon on 3 of the 5 factors compared between the two stocks. Get Polyrizon News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLRZ vs. The Competition Export to ExcelMetricPolyrizonPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$15,000.00$6.47B$5.31B$8.31BDividend YieldN/A2.64%5.20%4.10%P/E RatioN/A8.5926.6919.58Price / SalesN/A257.78393.58120.51Price / CashN/A65.8538.2534.62Price / BookN/A6.396.744.47Net IncomeN/A$143.98M$3.23B$248.32M7 Day PerformanceN/A-0.06%0.01%-1.26%1 Month PerformanceN/A1.64%8.69%10.52%1 Year PerformanceN/A-0.73%18.36%8.53% Polyrizon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLRZPolyrizonN/A$0.00-16.7%N/AN/A$15,000.00N/A0.00N/AGap DownHigh Trading VolumeUPCUniverse PharmaceuticalsN/A$4.91-4.1%N/A-99.6%$211,000.00$23.02M0.00220NCNANuCana2.1992 of 5 stars$0.03+5.2%$25.00+72,154.3%-98.9%$197,000.00N/A0.0030Gap DownHigh Trading VolumeHSTOHistogenN/A$0.03-4.6%N/A-82.4%$133,000.00$19,000.00-0.0120Gap DownSMFLSmart for LifeN/A$0.02+483.3%N/A-99.7%$124,000.00$11.11M0.00110Gap DownHigh Trading VolumeADTXAditxt0.8548 of 5 stars$1.66+1.8%N/A-100.0%$95,000.00$133,985.000.0060SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13,000.00N/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$6,000.00N/A0.00120GNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00N/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070News CoverageAnalyst ForecastARDSAridis PharmaceuticalsN/A$0.00flatN/A-99.7%$5,000.00$3.09M0.0030 Related Companies and Tools Related Companies Universe Pharmaceuticals Alternatives NuCana Alternatives Histogen Alternatives Smart for Life Alternatives Aditxt Alternatives Scopus BioPharma Alternatives Evelo Biosciences Alternatives Genocea Biosciences Alternatives Genocea Biosciences Alternatives Aridis Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLRZ) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Polyrizon Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Polyrizon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PLRZ Stock Free PLRZ Stock Alerts